A multi-centre, double-blind, placebo-controlled, randomised phase III trial to compare efficacy and safety of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in post-menopausal women with HR+ / HER2- metastatic breast cancer with non-visceral disease